相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Apalutamide and Overall Survival in Prostate Cancer
Matthew R. Smith et al.
EUROPEAN UROLOGY (2021)
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide
M. Del Re et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2021)
Targeting the p300/CBP Axis in Lethal Prostate Cancer
Jonathan Welti et al.
CANCER DISCOVERY (2021)
Characterization of FGFR signaling in prostate cancer stem cells and inhibition via TKI treatment
Juyeon Ko et al.
Oncotarget (2021)
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer
Alec Paschalis et al.
CANCER RESEARCH (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
TALAPRO-2: A placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC).
Neeraj Agarwal et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
Joaquin Mateo et al.
LANCET ONCOLOGY (2020)
Androgen Receptor in Breast Cancer-Clinical and Preclinical Research Insights
Aristomenis Anestis et al.
MOLECULES (2020)
Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype
C. Lu et al.
ANNALS OF ONCOLOGY (2020)
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer
Heidi Fettke et al.
EUROPEAN UROLOGY (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Cora N. Sternberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Neal D. Shore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cardiovascular Disease and Androgen Axis-Targeted Drugs for Prostate Cancer
Celestia S. Higano
NEW ENGLAND JOURNAL OF MEDICINE (2020)
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies
D. J. Khalaf et al.
ANNALS OF ONCOLOGY (2020)
Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer
E. David Crawford et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Preclinical profile of EPI-7386, a second-generation N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer
R. Le Moigne et al.
ANNALS OF ONCOLOGY (2020)
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Posttranslational regulation of androgen dependent and independent androgen receptor activities in prostate cancer
Simeng Wen et al.
ASIAN JOURNAL OF UROLOGY (2020)
ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
Taavi Neklesa et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Abiraterone acetate plus prednisone in patients with newly Croatia& diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
Karim Fizazi et al.
LANCET ONCOLOGY (2019)
Genomic correlates of clinical outcome in advanced prostate cancer
Wassim Abida et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Has the PROPHECY of AR-V7 Been Fulfilled?
Bram De Laere et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Dissecting Prognostic From Predictive Utility: Circulating AR-V7 Biomarker Testing for Advanced Prostate Cancer
Adam Sharp et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Kim N. Chi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function
Bin Gui et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer
Bo Liu et al.
CLINICAL CANCER RESEARCH (2019)
Abiraterone in High- and Low-risk Metastatic Hormone-sensitive Prostate Cancer
Alex P. Hoyle et al.
EUROPEAN UROLOGY (2019)
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
E. J. Small et al.
ANNALS OF ONCOLOGY (2019)
Optimizing Cancer Treatment Using Game Theory A Review
Katerina Stankova et al.
JAMA ONCOLOGY (2019)
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
Daniel J. Khalaf et al.
LANCET ONCOLOGY (2019)
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer
Bram De Laere et al.
CLINICAL CANCER RESEARCH (2019)
Membrane-associated androgen receptor (AR) potentiates its transcriptional activities by activating heat shock protein 27 (HSP27)
Jianzhuo Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Effect of HER3 dimer feedback upregulation via PI3K-AKT-mTOR pathway inhibition on androgen receptor (AR) stabilization in metastatic prostate cancer.
Myria Galazi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
TAS3681, a novel type of AR antagonist with AR downregulating activity, as a new targeted therapy for aberrant AR-driven prostate cancer.
Masanao Seki et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?
Emmanuel S. Antonarakis
LANCET ONCOLOGY (2018)
Metastatic Prostate Cancer
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells
Lingling Fan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date
Julio T. Chong et al.
ONCOTARGETS AND THERAPY (2018)
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
Matti Annala et al.
CANCER DISCOVERY (2018)
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer
Howard I. Scher et al.
JAMA ONCOLOGY (2018)
Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer
Karim Fizazi et al.
CLINICAL GENITOURINARY CANCER (2018)
CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions
Michal Zimmermann et al.
NATURE (2018)
Small Molecule Inhibitors of HSF1-Activated Pathways as Potential Next-Generation Anticancer Therapeutics
Chiranjeev Sharma et al.
MOLECULES (2018)
Investigating Genomic Aberrations of the Androgen Receptor: Moving Closer to More Precise Prostate Cancer Care?
Joaquin Mateo et al.
EUROPEAN UROLOGY (2017)
Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
Tomasz M. Beer et al.
EUROPEAN UROLOGY (2017)
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration- Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. D. James et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer
Ping Mu et al.
SCIENCE (2017)
Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer
Jianneng Li et al.
ELIFE (2017)
Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer
Laura Cato et al.
ELIFE (2017)
Androgen Receptor Signaling in Salivary Gland Cancer
Martin G. Dalin et al.
CANCERS (2017)
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
V. Conteduca et al.
ANNALS OF ONCOLOGY (2017)
Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy
Zhenfei Li et al.
NATURE (2016)
The Role of Steroid Receptor Coactivators in Hormone Dependent Cancers and Their Potential as Therapeutic Targets
Lei Wang et al.
HORMONES & CANCER (2016)
Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy Effects of Androgen-Deprivation Therapy
Maxine Sun et al.
JAMA ONCOLOGY (2016)
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
Alexander W. Wyatt et al.
JAMA ONCOLOGY (2016)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer
Daniel Tamae et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2015)
Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer
Eleni Efstathiou et al.
EUROPEAN UROLOGY (2015)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan et al.
LANCET ONCOLOGY (2015)
Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations
Hongli Liu et al.
MOLECULAR BIOSYSTEMS (2015)
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
Zhenfei Li et al.
NATURE (2015)
Plasma AR and abiraterone-resistant prostate cancer
Alessandro Romanel et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis
Frank Kunath et al.
BMJ OPEN (2015)
Targeting heat shock proteins in metastatic castration-resistant prostate cancer
Arun A. Azad et al.
NATURE REVIEWS UROLOGY (2015)
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects
R. Ferraldeschi et al.
ONCOGENE (2015)
High Progesterone Receptor Expression in Prostate Cancer Is Associated with Clinical Failure
Thea Grindstad et al.
PLOS ONE (2015)
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Philip A. Watson et al.
NATURE REVIEWS CANCER (2015)
Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).
Eric Jay Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The role of mRNA splicing in prostate cancer
Anna V. Lapuk et al.
ASIAN JOURNAL OF ANDROLOGY (2014)
Androgen receptor signaling in prostate cancer
Zoran Culig et al.
CANCER AND METASTASIS REVIEWS (2014)
Aggressive Variants of Castration-Resistant Prostate Cancer
Himisha Beltran et al.
CLINICAL CANCER RESEARCH (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer
Dayong Wu et al.
NUCLEIC ACIDS RESEARCH (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Changing Natural History of Metastatic Prostate Cancer
Ajjai Alva et al.
CANCER JOURNAL (2013)
Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
Vivek K. Arora et al.
CELL (2013)
A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
Kai-Hsiung Chang et al.
CELL (2013)
Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity
Himisha Beltran et al.
EUROPEAN UROLOGY (2013)
An evolving understanding of nuclear receptor coregulator proteins
Christopher J. Millard et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2013)
An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
Manav Korpal et al.
CANCER DISCOVERY (2013)
Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines
A. S. Cheung et al.
ANDROLOGY (2013)
New Agents for the Management of Castration-Resistant Prostate Cancer
Robert J. Cersosimo
ANNALS OF PHARMACOTHERAPY (2012)
Androgen Receptor on the Move: Boarding the Microtubule Expressway to the Nucleus
Maria Thadani-Mulero et al.
CANCER RESEARCH (2012)
Structural features discriminate androgen receptor N/C terminal and coactivator interactions
Emily B. Askew et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Androgen receptor coregulators: Recruitment via the coactivator binding groove
Dennis J. van de Wijngaart et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi et al.
LANCET ONCOLOGY (2012)
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso et al.
NATURE (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
Yasser Rehman et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2012)
Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1
Changmeng Cai et al.
CANCER CELL (2011)
Clusterin Inhibition Using OGX-011 Synergistically Enhances Hsp90 Inhibitor Activity by Suppressing the Heat Shock Response in Castrate-Resistant Prostate Cancer
Francois Lamoureux et al.
CANCER RESEARCH (2011)
Management of Side Effects of Androgen Deprivation Therapy
Mathis Grossmann et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2011)
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor et al.
CANCER CELL (2010)
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
Philip A. Watson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Combined Androgen Blockade With Bicalutamide for Advanced Prostate Cancer Long-Term Follow-Up of a Phase 3, Double-Blind, Randomized Study for Survival
Hideyuki Akaza et al.
CANCER (2009)
Increased Expression of Androgen Receptor Sensitizes Prostate Cancer Cells to Low Levels of Androgens
Kati K. Waltering et al.
CANCER RESEARCH (2009)
International epidemiology of prostate cancer: Geographical distribution and secular trends
Peter D. Baade et al.
MOLECULAR NUTRITION & FOOD RESEARCH (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients
P. McCall et al.
BRITISH JOURNAL OF CANCER (2008)
Characterization of nuclear import of the domain-specific androgen receptor in association with the importin α/β and Ran-guanosine 5′-triphosphate systems
Natsuko Kaku et al.
ENDOCRINOLOGY (2008)
Testosterone surge: Rationale for gonadotropin-releasing hormone blockers?
Hendrik van Poppel et al.
UROLOGY (2008)
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth
Qianben Wang et al.
MOLECULAR CELL (2007)
Compartmentalization of androgen receptor protein-protein interactions in living cells
Martin E. van Royen et al.
JOURNAL OF CELL BIOLOGY (2007)
Male pubertal development and the role of androgen therapy
Erick J. Richmond et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2007)
International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: Glucocorticoid, mineralocorticoid, progesterone, and androgen receptors
Nick Z. Lu et al.
PHARMACOLOGICAL REVIEWS (2006)
Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer
Zongxiang Zhou et al.
CANCER RESEARCH (2006)
Molecular chaperones throughout the life cycle of the androgen receptor
J Prescott et al.
CANCER LETTERS (2006)
Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions
J Duff et al.
MOLECULAR ENDOCRINOLOGY (2005)
The structural basis of androgen receptor activation: Intramolecular and intermolecular amino-carboxy interactions
F Schaufele et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer
MA Titus et al.
CLINICAL CANCER RESEARCH (2005)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)
Adrenal androgens and intracrinology
F Labrie
SEMINARS IN REPRODUCTIVE MEDICINE (2004)
Molecular mechanisms of androgen receptor-mediated gene regulation: structure-function analysis of the AF-1 domain
IJ McEwan
ENDOCRINE-RELATED CANCER (2004)
The role of hepatocyte nuclear factor-3α (forkhead box A1) and androgen receptor in transcriptional regulation of prostatic genes
N Gao et al.
MOLECULAR ENDOCRINOLOGY (2003)
Mechanism of antiandrogen action:: Key role of Hsp90 in conformational change and transcriptional activity of the androgen receptor
V Georget et al.
BIOCHEMISTRY (2002)
Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer
K Steketee et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Molecular biology of the androgen receptor
EP Gelmann
JOURNAL OF CLINICAL ONCOLOGY (2002)
A role for GATA transcription factors in the androgen regulation of the prostate-specific antigen gene enhancer
CM Perez-Stable et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2000)
FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor
B He et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis
J Seidenfeld et al.
ANNALS OF INTERNAL MEDICINE (2000)
分享论文
